Squamous cell carcinoma of skin

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • Philogen S.p.A. Commercial
    BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
    2024-518530-92-00 2 countries 2024 n=78
    Ended

Phase I

1 trial
  • Kupando GmbH Commercial
    IMP not specified
    2025-522402-21-00 1 country 2026 n=21
    Recruiting

Phase I (First in Human)

1 trial
  • Checkpoint Therapeutics Inc. Commercial
    IMP not specified
    2024-517536-22-00 2 countries 2020 n=63
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Kupando GmbH Commercial 1 Phase I 1
Philogen S.p.A. Commercial 1 Phase II 0
Checkpoint Therapeutics Inc. Commercial 1 Phase I (First in Human) 0
New trials by year
2020
1
2024
1
2026
1
← All indication landscapes